Aprepitant in refractory pruritus of systemic lymphoproliferative disorders

Pulido-Pérez, A. (Ana); Lopez, A. (A.); Bergón-Sendín, M. (Marta); Nieto-Benito, L.M. (Lula M.); Romero-Jimenez, R. (R.); Dorado-Herrero, N. (N.); Bastos-Oreiro, M.B. (M.B.); Suárez-Fernández, R. (Ricardo)

Authors:

Pulido-Pérez, A. (Ana)

Lopez, A. (A.)

Bergón-Sendín, M. (Marta)

Nieto-Benito, L.M. (Lula M.)

Romero-Jimenez, R. (R.)

Dorado-Herrero, N. (N.)

Bastos-Oreiro, M.B. (M.B.)

Suárez-Fernández, R. (Ricardo)

Keywords:

Materias Investigacion::Ciencias de la Salud
Materias Investigacion::Ciencias de la Salud::Dermatología
Lymphoproliferative disorders
Primary cutaneous T-cell lymphomas (CTCL).

Issue Date:

2020

Publisher:

Wiley

ISSN:

1468-3083
32180276

Citation:

Pulido-Pérez, A. (Ana); Carretero-Lopez, A. (A.); Bergón-Sendín, M. (Marta); et al. "Aprepitant in refractory pruritus of systemic lymphoproliferative disorders". Journal of the European Academy of Dermatology and Venereology. 34 (8), 2020, e422 - e424

Abstract

araneoplastic pruritus represents a frequent symptom in the debut or progression of lymphoproliferative disorders. It affects approximately 30% of patients with Hodgkin lymphoma and 15% of patients with non-Hodgkin lymphoma.1 Aprepitant has shown promising results in the treatment of refractory pruritus of primary cutaneous T-cell lymphomas (CTCL).

URI:

https://hdl.handle.net/10171/68850

DOI:

10.1111/jdv.16370

Appears in Collections:

DA - CUN - Dermatología médico-quirúrgica y venereológica - Artículos de revista

Files in This Item: